These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 32627280)

  • 21. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.
    Zhu B; Ren C; Du K; Zhu H; Ai Y; Kang F; Luo Y; Liu W; Wang L; Xu Y; Jiang X; Zhang Y
    Biochem Pharmacol; 2019 Dec; 170():113642. PubMed ID: 31541631
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cisplatin resistance in lung cancer is mediated by MACC1 expression through PI3K/AKT signaling pathway activation.
    Zhang Q; Zhang B; Sun L; Yan Q; Zhang Y; Zhang Z; Su Y; Wang C
    Acta Biochim Biophys Sin (Shanghai); 2018 Aug; 50(8):748-756. PubMed ID: 29961813
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FOXC2 promotes epithelial-mesenchymal transition and cisplatin resistance of non-small cell lung cancer cells.
    He Y; Xie H; Yu P; Jiang S; Wei L
    Cancer Chemother Pharmacol; 2018 Dec; 82(6):1049-1059. PubMed ID: 30302523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells.
    Tyler A; Johansson A; Karlsson T; Gudey SK; Brännström T; Grankvist K; Behnam-Motlagh P
    Exp Cell Res; 2015 Aug; 336(1):23-32. PubMed ID: 26004871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Silence of fibronectin 1 increases cisplatin sensitivity of non-small cell lung cancer cell line.
    Gao W; Liu Y; Qin R; Liu D; Feng Q
    Biochem Biophys Res Commun; 2016 Jul; 476(1):35-41. PubMed ID: 27207836
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cucurbitacin B Induces the Lysosomal Degradation of EGFR and Suppresses the CIP2A/PP2A/Akt Signaling Axis in Gefitinib-Resistant Non-Small Cell Lung Cancer.
    Liu P; Xiang Y; Liu X; Zhang T; Yang R; Chen S; Xu L; Yu Q; Zhao H; Zhang L; Liu Y; Si Y
    Molecules; 2019 Feb; 24(3):. PubMed ID: 30759826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Downregulation of HIF-2α Reverse the Chemotherapy Resistance of Lung Adenocarcinoma A549 Cells to Cisplatin.
    Gao ZJ; Yuan WD; Yuan JQ; Yuan K; Wang Y
    Med Sci Monit; 2018 Feb; 24():1104-1111. PubMed ID: 29469087
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SKA1 regulates the metastasis and cisplatin resistance of non-small cell lung cancer.
    Shen L; Yang M; Lin Q; Zhang Z; Miao C; Zhu B
    Oncol Rep; 2016 May; 35(5):2561-8. PubMed ID: 26985856
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of autophagy by andrographolide resensitizes cisplatin-resistant non-small cell lung carcinoma cells via activation of the Akt/mTOR pathway.
    Mi S; Xiang G; Yuwen D; Gao J; Guo W; Wu X; Wu X; Sun Y; Su Y; Shen Y; Xu Q
    Toxicol Appl Pharmacol; 2016 Nov; 310():78-86. PubMed ID: 27639426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of ERK1/2 and Akt is associated with cisplatin resistance in human lung cancer cells.
    Wang M; Liu ZM; Li XC; Yao YT; Yin ZX
    J Chemother; 2013 Jun; 25(3):162-9. PubMed ID: 23783141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversal of cisplatin resistance by inhibiting PI3K/Akt signal pathway in human lung cancer cells.
    Zhang Y; Bao C; Mu Q; Chen J; Wang J; Mi Y; Sayari AJ; Chen Y; Guo M
    Neoplasma; 2016; 63(3):362-70. PubMed ID: 26925782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway.
    Zhang Q; Yang J; Bai J; Ren J
    Cancer Sci; 2018 Apr; 109(4):944-955. PubMed ID: 29383798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Knockdown of CABYR-a/b increases chemosensitivity of human non-small cell lung cancer cells through inactivation of Akt.
    Qian Z; Li M; Wang R; Xiao Q; Wang J; Li M; He D; Xiao X
    Mol Cancer Res; 2014 Mar; 12(3):335-47. PubMed ID: 24362251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nrf2/p‑Fyn/ABCB1 axis accompanied by p‑Fyn nuclear accumulation plays pivotal roles in vinorelbine resistance in non‑small cell lung cancer.
    Tamari S; Menju T; Toyazaki T; Miyamoto H; Chiba N; Noguchi M; Ishikawa H; Miyata R; Kayawake H; Tanaka S; Yamada Y; Yutaka Y; Nakajima D; Ohsumi A; Hamaji M; Date H
    Oncol Rep; 2022 Oct; 48(4):. PubMed ID: 35959810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 40. miR-186-5p targeting SIX1 inhibits cisplatin resistance in non-small-cell lung cancer cells (NSCLCs).
    Liu X; Zhou X; Chen Y; Huang Y; He J; Luo H
    Neoplasma; 2020 Jan; 67(1):147-157. PubMed ID: 31686523
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.